Orelabrutinib is an Orally Active BTK Inhibitor for B Cell Malignancies Research
B cell lymphoma is a kind of non-Hodgkin lymphoma (NHL) and comprises a diverse group of malignant diseases. However, about 1/3 patients with B-NHL developed relapsed or refractory diseases. Bruton…